StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research note released on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.
BioLineRx Stock Performance
BLRX stock opened at $0.46 on Tuesday. BioLineRx has a twelve month low of $0.43 and a twelve month high of $1.93. The business’s fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $0.66. The firm has a market cap of $36.93 million, a price-to-earnings ratio of -0.61 and a beta of 1.46. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.
BioLineRx (NASDAQ:BLRX – Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million. Analysts predict that BioLineRx will post -0.25 earnings per share for the current year.
Institutional Trading of BioLineRx
BioLineRx Company Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
See Also
- Five stocks we like better than BioLineRx
- How to Invest in the FAANG Stocks
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Using the MarketBeat Dividend Tax Calculator
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Conference Calls and Individual Investors
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.